Zevra to finish what Orphazyme started: "We have set ourselves up for success"

Zevra Therapeutics, which bought Orphazyme’s failed rare disease candidate last year, has what the embattled developer needed: time and money.
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Orphazyme’s former drug candidate arimoclomol had already been rejected by the US Food and Drug Administration (FDA) – and was likely about to be rejected by the European Medicines Agency (EMA) as well, before the developer retracted its marketing application. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading